Related Experiment Videos
Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation
Partow Kebriaei1, Jane N Winter, Ginna G Laport
1Department of Medicine and Cancer Research Center, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637, USA.
Leukemia Research
|April 8, 2004
Summary
A stem cell transplant recipient achieved remission from chronic myeloid leukemia (CML) despite graft rejection and the emergence of clonal hematopoiesis. This case offers insights into therapy-related leukemogenesis and long-term transplant outcomes.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- A 22-year-old male with chronic myeloid leukemia (CML) underwent a stem cell transplant (SCT).
- The transplant involved fractionated total body irradiation (TBI) and etoposide chemotherapy, followed by infusion of HLA-matched maternal CD34+ selected stem cells.
- Post-transplant immunosuppression included antithymocyte globulin, cyclosporine, and prednisone.
Observation:
- The donor graft was rejected two years post-SCT.
- Despite graft rejection, the patient remained clinically well with normal blood counts.
- Multiple clones with balanced translocations and deletions were present in host bone marrow cells for over six years post-SCT.
Findings:
- The patient achieved long-term remission from CML and showed no evidence of myelodysplasia.
- The persistence of host clonal hematopoiesis did not impede long-term remission or clinical well-being.
- The case demonstrates successful CML management despite graft rejection and ongoing host chromosomal abnormalities.
Implications:
- The emergence of clonal hematopoiesis in SCT recipients warrants further investigation.
- This case may provide insights into the mechanisms of therapy-related leukemogenesis.
- Understanding the interplay between graft rejection, clonal hematopoiesis, and long-term outcomes is crucial for optimizing SCT strategies.